Introduction: A qualitative detection method for EGFR mutations is not sufficient to guide precise targeted therapy in clinical practice. The aim of this study was to explore the relationship between the abundance of EGFR mutations and efficacy of EGFR tyrosine kinase inhibitors (TKIs).
Introduction
For patients with advanced NSCLC with EGFR activating mutations, EGFR tyrosine kinase inhibitors (TKIs) can significantly improve the progression-free survival (PFS) and overall survival (OS). [1] [2] [3] [4] However, even in patients found to be positive for EGFR activating mutations, 10% to 30% could not obtain an objective response and could even experience rapid disease progression. [1] [2] [3] [4] As of now, little is known about the mechanisms of primary resistance to EGFR TKIs, although several possible mechanisms have been revealed. [5] [6] [7] [8] [9] Of these mechanisms, intratumoral heterogeneity resulted from tumor clonal evolution may be the most important. [10] [11] [12] [13] Because intratumoral genetic heterogeneity of NSCLC and tumor clonal evolution have been demonstrated by several studies, [14] [15] [16] [17] [18] [19] [20] the clonal construction of NSCLC should be depicted more comprehensively and finely during the whole process of all therapies by a sensitive method. As a result, the concept of "abundance of oncogenic driver" was presented. EGFR-mutant and EGFR wild-type tumor regions could exist concurrently in the same primary NSCLC 21, 22 ; therefore, investigators considered that the abundances of EGFR mutations were different between individual tumors and even between biopsy samples obtained from the same tumor at different time points during targeted therapy. Early in 2011, Zhou et al. inferred that the abundance of EGFR mutations actually existed by comparing different results of detection of the same NSCLC tissue by two detection methods with different sensitivities (1% by the amplification refractory mutation system [ARMS] method versus 10% by direct sequencing), and demonstrated that the abundance of EGFR mutations was significantly associated with efficacy of EGFR TKIs. 23 However, Zhou, et al. did not use a quantitative method to evaluate the abundance of EGFR mutations and did not reveal the real reason behind the relationship between abundance of EGFR mutations and efficacy of EGFR TKIs.
As we know, another important mechanism of primary resistance to EGFR TKIs is de novo EGFR T790M mutation, which can result in a gatekeeper in the adenosine triphosphate combined domain. 9 At present, the prevalence of de novo EGFR T790M mutation in patients with NSCLC before EGFR TKI therapy was found to be obviously higher than previously believed because of elevated sensitivity of detection methods. 9, [24] [25] [26] Actually, the boundary between acquired resistance and de novo resistance to TKIs in clinical practice is becoming blurred with the development of detection methods. Moreover, preexisting and secondary EGFR T790M mutation also cannot be distinguished clearly by existing detection methods. Preexisting T790M mutation could be mistaken for secondary mutation if the detection method was not sensitive enough. The BELIEF study demonstrated that patients with primary T790M treated with EGFR TKIs in combination with bevacizumab obtained significantly better efficacy than those treated with single EGFR TKIs. 27 Meanwhile, for patients with acquired EGFR T790M mutation, osimertinib has been demonstrated to be the better choice. 28 Thus, according to what standards should we make a clinical decision? According to clinically acquired/de novo resistance to EGFR TKIs or the abundance of EGFR activating mutations determined by a high-sensitivity method? Moreover, the abundance of both activating and resistant EGFR mutations may be changing under the pressure of treatment. 29 Therefore, a quantitative, convenient, highly sensitive, low-cost, and easy-to-interpret method is required for diagnosis and efficacy monitoring during the process of therapy. Moreover, a cutoff value determined by receiver operating characteristic (ROC) analysis in training and validation groups was used to minimize the false positives because its high sensitivity was up to 0.1%. Finally, we used the ARMS method optimized with competitive blockers and specific mutation quantitation (ARMSþ) to test EGFR status in circulating tumor DNA (ctDNA) extracted from peripheral blood and explored the concordance of detection results between ctDNA and tumor tissue.
Methods

Study Design and Participants
A total of 201 patients with NSCLC who were treated with first-generation EGFR TKIs regardless of treatment lines and 42 untreated patients were recruited with informed consent between September 2008 and December 2012 in Shanghai Pulmonary Hospital at Tongji University (see the flowchart in Supplementary Fig. 1 ). All patients provided formalin-fixed paraffin-embedded samples. All specimens were diagnosed as NSCLC, and well-trained, experienced pathologists confirmed that the tumor cell content was more than 50%. All samples had sufficient tumor tissues for analysis. DNA was extracted with a QIAmp DNA Formalin-Fixed Paraffin-Embedded Tissue Kit (Qiagen, Hilden, Germany) following the manufacturer's protocol. For determining the cutoff values, only patients with a single mutation type were included in the statistical analysis. Patients with double activating mutations were classified as the predominant mutation group according to the abundance of mutations; patients with primary T790M mutation were classified as belonging to the wild-type group.
The study protocol was approved by the Ethical Committee of Shanghai Pulmonary Hospital, Tongji University. Written informed consent was received from patients before inclusion in the study.
Abundance of EGFR Mutations in Tumor Tissue/ ctDNA Samples by ARMSþ
The common EGFR mutations, including exon 19 deletion (745-750 deletion and 745-751 deletion) (19DEL), exon 21 point mutation (L858R), and exon 20 point mutation (T790M) were detected by using ARMSþ (Human EGFR Gene Mutation Quantitative Detection Kit, Genosaber Biotech, Shanghai, People's Republic of China) according to the manufacturer's instructions (see the Supplementary Materials for details). The copies of all mutations and EGFR locus were calculated by standard curve. The abundance of EGFR mutation in a tumor tissue sample was defined as follows: mutation abundance % ¼ copies of EGFR mutants/copies of EGFR locus Â 100%. To avoid false-positive or false-negative results, the samples with fewer than 100 copies of the EGFR locus were censored in this test. The tumor tissue samples were also tested for EGFR mutant status by the ARMS method and direct sequencing. The abundance of EGFR mutations in ctDNA from plasma was defined as EGFR mutation copies per milliliter. The cutoff values of 19DEL, L858R, and T790M were two, five, and three copies per milliliter, respectively (see the Supplementary Materials for definition of the cutoff value).
Statistical Analysis
The whole study population was divided into training and validations set by stratified random sampling (see the study flowchart in Supplementary Fig. 1 ). The cutoff value of abundance was determined by the ROC curve. PFS was defined as the time from commencement of gefitinib or erlotinib treatment to confirmed disease progression or death of any cause. The median PFS times were analyzed by Kaplan-Meier analysis and compared among testing groups by using the log-rank test. A multivariate Cox proportional hazards regression model was performed to evaluate independent predictive factors associated with PFS. The objective response rate (ORR), disease control rate, and relationship between EGFR mutant abundance and other clinical characteristics were evaluated by Pearson's chi-square test or Fisher's exact test. Statistical significance was set at a p value (two sided) of 0.05 or less.
Results
Significant Relationship between the Abundance of EGFR Activating Mutations and ORR of EGFR TKIs in NSCLC
The abundance of EGFR activating mutations by ARMSþ was significantly associated with objective response to EGFR TKIs (Fig. 1) . Of the 201 patients, 72 harbored 19DEL with a median abundance of 37.86% (range 0.13%-98.62%). In the 63 patients with L858R, the median abundance was 20.14% (range 0.12%-56.19%) (see Fig. 1 ). The sensitivity of ARMSþ was up to 0.1%, which was demonstrated by an incorporation experiment ( Supplementary Fig. 2 ). We also analyzed the variation of EGFR mutant abundance in three different paraffin-fixed samples from each of 26 patients. Mutation abundance in the different paraffin sections from primary tumor was similar (p ¼ 0.746 for 19DEL and p ¼ 0.103 for L858R [according to multivariate analysis of variance of repeated measuring, as shown in Supplementary Fig. 3] ). As seen in Figure 1A , the abundance of 19DEL was significantly higher than that of L858R. Moreover, the abundance of EGFR activating mutations was significantly associated with objective response to EGFR TKIs in both the 19DEL and L858R groups (Fig. 1B-E) . Therefore, the cutoff value of abundance was set by ROC analysis according to objective response to EGFR TKIs in the training group and validated in the validation group. There was no significant difference in clinicopathologic features of patients between the training and validation groups (Supplementary Table 1 Table 2 ).
Impact of Abundance of EGFR Activating Mutations on Response to TKIs
As previous research has shown, we also found that the median PFS after EGFR TKI treatment in the 19DEL group was numerically superior to that in the L858R group, although the difference did not reach statistical significance ( Supplementary Fig. 4 ). The median PFS times for the 19DEL, L858R and wild-type groups were 13.6 months (95% CI: 10.7-16.5), 7.7 months (95% CI: 4.1-11.3), and 2.0 months (95% CI: 0.9-3.1), respectively. The median PFS in high group was distinctly longer than in low and wild-type groups, whether for 19DEL or L858R in total population ( Fig. 2A and B) . In the training set, whether for 19DEL or for L858R, the median PFS in the high group was significantly longer than in the low group (15.0 versus 2.0 months for 19DEL [p < 0.001] and 12.3 versus 2.0 months for L858R [p < 0.001]) ( Fig. 2C and D) . Similar results were observed in the validation set ( Fig. 2E and F) . The median PFS times were 15.0 months for 19DEL and 8.0 months for L858R with abundance above the cutoff, respectively, whereas in the patients in the low group, the respective median PFS times were 2.0 months for 19DEL and 1.9 months for L858R.
Comparison of Response to EGFR TKIs between the WT and Mutant Groups by ARMSþ, ARMS, and Direct Sequencing
In this study, all samples were also detected by two qualitative methods, ARMS and direct sequencing. The concordance values between ARMSþ and the ARMS method or direct sequencing were 94.5% and 73.1%, respectively (Supplementary Table 3 ) if patients with a low abundance of EGFR activating mutations were classified into the EGFR mutant group. However, patients with a low abundance of EGFR mutations did not achieve a good response to EGFR TKIs (Fig. 3) .
The ORR in response to EGFR TKIs for patients with a low abundance of EGFR activating mutations was similar to that for patients with wild-type EGFR, which was significantly lower than that for patients with a high abundance of EGFR activating mutations (Supplementary Table 4 ). In addition, the PFS of patients with a low abundance of EGFR mutation was also similar to that of patients in the EGFR wild-type group (see Fig. 3 ).
Impact of T790M Mutant Abundance on Efficacy of EGFR TKIs
Of the 201 enrolled patients with NSCLC, 13 were identified as harboring harbor T790M mutation in tumor tissues. The clinicopathologic characteristics of these 13 patients with T790M mutation are shown in Table 1 . Nine of these patients achieved a partial response and four patients achieved stable disease in response to EGFR TKIs. We did not find a correlation between PFS in response to EGFR TKIs and the abundance of EGFR T790M mutations in tumor tissues, which may be a result of small sample size. However, most of the patients with a partial response to EGFR TKIs (seven of the nine) were determined to have a low abundance of T790M mutations. In addition, the remaining two patients with a PFS longer than 12 months were concurrently identified to have a high abundance of EGFR activating mutations. However, there was no statistically significant relationship between the abundance of EGFR T790M mutation and PFS in response to EGFR TKIs in this study.
Relationship between Number of Copies of EGFR Activating Mutations from ctDNA and Abundance from Matched Tissue
A total of 42 matched plasma samples from patients with advanced NSCLC in this study were available for ctDNA extraction and testing for number of copies of Progression-free survival (PFS) in the groups stratified by the cutoff value of mutant abundance. The PFS of three groups according to mutant abundance of exon 19 deletion (A) or L858R (B) (the high group consists of patients with a mutant abundance greater than or equal to the cutoff, the low group consists of patients with a mutant abundance less than the cutoff and greater than 0.1%, and the wild-type [WT] group consists of wild-type patients). The PFS of the two groups is stratified by the cutoff value of exon 19 deletion (4.9%) (C) and L858R (9.5%) (D) mutant abundance in the training set, respectively. The PFS of the two groups is stratified by the cutoff value of exon 19 deletion (4.9%) (E) and L858R (9.5%) (F) mutant abundance in the validation sets, respectively. CI, confidence interval.
EGFR activating mutations from ctDNA. Of them, 40 patients were positive for EGFR mutations in tumor tissue (17 for L858R and 23 for 19DEL) and two were negative for EGFR mutations in both tumor tissue and ctDNA. Of 17 tumors harboring the EGFR L858R mutation, 14 matched ctDNA samples were positive for L858R mutation. Of 23 tumors harboring EGFR 19DEL mutations, 19 matched ctDNA samples were positive for 19DEL. The Spearman rank correlation analysis between the abundance of EGFR activating mutations from tumor tissue and the number of copies of EGFR activating mutations from matched ctDNA showed a correlation coefficient of 0.468 with a p value of 0.005. The abundance of EGFR mutations appeared to be more significantly associated with the number of copies of EGFR mutations in 19DEL group (Fig. 4) . Figure 3 . The difference in response to EGFR (tyrosine kinase inhibitors) TKIs and progression-free survival in response to EGFR TKIs between patients with EGFR wild-type NSCLC and those with EGFR-mutant NSCLC identified by the amplification refractory mutation system (ARMS) optimized with competitive blockers and specific mutation quantitation (ARMSþ), ARMS, and sequencing. The patients with EGFR mutations by ARMS but low abundance of EGFR mutations by ARMSþ from tumor tissues may achieve few benefits from EGFR TKIs. (A) The percentages of patients who achieved a partial response, stable disease, or progressive disease differed with the change of abundance of EGFR mutations in this study (numerals are numbers of patients). Progression-free survival of the groups stratified according to specific mutation status for exon 19 deletions (B) and L858R (C) by the ARMS method and ARMSþ. ARMS-P, positive group with a positive result by ARMS; ARMS-N, group with a negative result by ARMS; ARMS-P, H, patients with a mutation abundance higher than or equal to the cutoff by ARMSþ in the ARMS-P group; ARMS-P, L, patients with mutation abundance lower than the cutoff and greater than 0.1% by ARMSþ in the ARMS-P group; CI, confidence interval.
Discussion
Intratumoral heterogeneity is one of the most important causes of treatment failure for malignant tumors. None of precise targeted therapies can escape the fate of resistance in the face of malignant tumor with complicated clonal compositions. Therefore, we should use a quantitative detection with high sensitivity to explore the effect of EGFR mutation abundance on efficacy of EGFR TKIs to delay the emergence of resistance. We found that the abundance of EGFR activating mutations was significantly positively associated with efficacy of EGFR TKIs when quantitative ARMSþ was used. In addition, the relationship between the abundance of EGFR T790M and resistance to EGFR TKIs and the relationship between number of copies of EGFR mutations in circulating free DNA (cfDNA, the fragmentation of DNA in blood stream) and the abundance of EGFR mutations in tissue were both explored in our study. First, we found that the abundance of EGFR activating mutations, including 19DEL and L858R, was significantly associated with response to EGFR TKIs. We used the cutoff values calculated by ROC analysis in the training group and validated them in the validation group to divide EGFR-mutant NSCLC into high and low groups to minimize the false positives. Patients with advanced EGFR-mutant NSCLC in the high group had a significantly higher ORR and longer PFS than those in the low group regardless of mutation pattern. A multivariate analysis (Supplementary Table 5 ) showed that high abundance was an independent predictive factor of longer PFS in addition to nonsmoking status and Eastern Cooperative Oncology Group performance status of 1 or lower. We inferred that low abundance of EGFR mutations caused by the intratumoral heterogeneity of a malignant tumor may contribute to primary resistance to EGFR TKIs. What we observed was similar to the results of a Japanese study in which EGFR L858R mutant allele frequency may be a potential predictive factor of TKI treatment efficacy. 30 For patients with a low abundance of EGFR activating mutations, a tumor clone with EGFR mutations may be limited whereas tumor clones without EGFR mutations may be predominant in the primary tumor. Therefore, for patients with advanced NSCLC with low abundance EGFR activating mutations, a treatment strategy of first-line chemotherapy alone or in combination with EGFR TKIs should be explored in a further study. Second, we found that the abundance of 19 DEL was significantly higher than that of L858R, which can explain why the efficacy of EGFR TKIs in patients with 19 DEL was higher than in those with L858R. Previous study demonstrated that the binding affinity and response of L858R mutant to inhibitors were inferior to those of 19Del. [31] [32] [33] [34] Finally, we did not identify specific clinicopathologic features of low or high abundance of EGFR mutations. It seems impossible to identify NSCLC with a low abundance of EGFR mutations by specific clinicopathologic features. EGFR T790M is an important mechanism of resistance to EGFR TKIs. The frequency of primary T790M mutation (2.8% by direct sequencing and 25.2% by matrixassisted laser desorption/ionization time-of-flight mass spectrometry) was significantly associated with sensitivity of detection method. 9 The frequency of primary T790M was 6.5% in our study, which was consistent with previous studies. Su et al. reported that there was no significant difference in ORR between EGFR activating mutation concurrent with T790M and without T790M groups (56.5% versus 72.7% [p ¼ 0.257]), but PFS in the former was significantly shorter than in the latter (6.7 versus 10.2 months [p ¼0.030]). 9 The same phenomenon was also observed in our study. The possible reason for this difference may be attributed to limitation of efficacy evaluation with the Response Evaluation Criteria in Solid Tumors 1.1. We speculated that tumor shrinkage resulting from elimination of EGFR activating mutant clones would still occur whereas PFS would be shortened on account of proliferation of the T790M clone under the selection pressure of EGFR TKIs if the T790M clone was not predominant in the primary tumor. The degree of PFS shortening may be associated with the abundance of T790M. Certainly, we excluded other possible reasons for primary resistance to EGFR TKIs, including additional oncogenic drivers and BCL2 like 11 gene (BIM) deletion polymorphism. In addition, we also excluded the germline T790M mutation. EGFR TKIs in combination with bevacizumab could improve the PFS for patients with primary resistance to EGFR TKIs. 27 Osimertinib could overcome acquired EGFR T790M resistance to the first-generation EGFR TKIs. 28 However, Hata, et al. observed that some acquired EGFR T790M resistance can occur by selection of preexisting EGFR T790M -positive clones. 35 Actually, there is sometimes little difference between acquired resistance and primary resistance to TKIs in clinical practice. It may be better to establish treatment strategy on the basis of abundance of EGFR mutations. In addition, the abundance of both EGFR activating mutations and T790M mutation could be changing under the selection pressure of treatment in clinical practice. In a colorectal cancer study, the abundance of resistance mutation could increase after a long-time targeted therapy whereas sensitivity to EGFR TKIs could be regained after chemotherapy in combination with bevacizumab. 36 Therefore, dynamic monitoring of the abundance of EGFR mutations during the therapy is very important.
In addition, we also used the ARMSþ method to detect ctDNA for number of copies of EGFR mutations to explore the relationship between number of copies of EGFR mutations in ctDNA and the abundance of EGFR mutations in tumor tissue. A large noninterventional diagnostic ASSESS study has demonstrated that ctDNA is a feasible sample for EGFR mutation analysis with a high concordance of mutation status of 89% in 1162 matched NSCLC samples. 37 We also considered that ctDNA could be used in a qualitative diagnosis with a high-sensitivity detection method. However, the number of copies of EGFR mutations detected in cfDNA was not significantly positively related with the abundance of EGFR mutations in tissue in our study. We inferred that a possible reason for this was a low proportion of ctDNA in the cfDNA extracted from peripheral blood (range <0.1%-10%). Therefore, it is hard to evaluate the abundance of EGFR mutations in primary tumor by quantitatively detecting for EGFR mutations in cfDNA.
In conclusion, we explored the role of abundance of EGFR mutations in predicting efficacy of EGFR TKIs and analyzed the relationship between number of copies of an EGFR mutation in cfDNA and EGFR mutation abundance in tissue by using ARMSþ. The findings suggest that a low abundance of EGFR activating mutations may be one of possible mechanisms of primary resistance to EGFR TKIs and that an abundance of EGFR T790M mutation may have an adverse impact on PFS rather than on ORR for patients with advanced EGFR-mutant NSCLC treated with EGFR TKIs. The difference in abundance of EGFR mutations between individuals may be attributed to complex clonal evolution of tumor by selection pressure. So we did not find the specific clinicopathologic features of patients with advanced NSCLC with a low or high abundance of EGFR mutation. A quantitative diagnostic method may guide personalized therapy more precisely than traditional qualitative methods, delay the emergence of resistance, and maximize the benefits of treatment for advanced NSCLC.
